Europe
Rentschler Biopharma SE announced today that Henning Gerschewski (44) will join the company as Vice President Manufacturing Science and Technology, effective January 01, 2019. He will head a highly experienced team of senior scientists with the goal of ensuring technical leadership in process development and technology transfer activities.
AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.
Merck & Co. found itself with two new approvals this week. The FDA approved Lynparza (codeveloped by AstraZeneca and Merck) and also approved Merck’s Keytruda. Both of these drugs were approved for new indications.
Topline-data from first half of treatment period (one year)
InflaRx N.V. today announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
Epigenomics AG today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, the first and only FDA-approved blood test for colorectal cancer screening.
Recipharm today announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.
For the second time, Adrenomed and sphingotec host international scientific symposium on vascular integrity in Berlin
BioArctic AB announced today that Gunilla Andersson assumes the new position as Senior Director HR in the management team as of January 1, 2019.
Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.
PRESS RELEASES